8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Individual and Combined Impact of Oxygen and Oxygen Transporter Supplementation during Kidney Machine Preservation in a Porcine Preclinical Kidney Transplantation Model

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Marginal kidney graft preservation in machine perfusion (MP) is well-established. However, this method requires improvement in order to mitigate oxidative stress during ischemia-reperfusion, by using oxygenation or an O 2 carrier with anti-oxidant capacities (hemoglobin of the marine worm; M101). In our preclinical porcine (pig related) model, kidneys were submitted to 1h-warm ischemia, followed by 23 h hypothermic preservation in Waves ® MP before auto-transplantation. Four groups were studied: W (MP without 100%-O2), W-O 2 (MP with 100%-O2; also called hyperoxia), W-M101 (MP without 100%-O2 + M101 2 g/L), W-O 2 + M101 (MP with 100%-O2 + M101 2 g/L) ( n = 6/group). Results: Kidneys preserved in the W-M101 group showed lower resistance, compared to our W group. During the first week post-transplantation, W-O 2 and W-M101 groups showed a lower blood creatinine and better glomerular filtration rate. KIM-1 and IL-18 blood levels were lower in the W-M101 group, while blood levels of AST and NGAL were lower in groups with 100% O2. Three months after transplantation, fractional excretion of sodium and the proteinuria/creatinuria ratio remained higher in the W group, creatininemia was lower in the W-M101 group, and kidney fibrosis was lower in M101 groups. We concluded that supplementation with M101 associated with or without 100% O2 improved the Waves ® MP effect upon kidney recovery and late graft outcome.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: not found

          Chronic renal allograft dysfunction.

          The major causes of renal transplant loss are death from vascular, malignant or infectious disease, and loss of the allograft from chronic renal dysfunction associated with the development of graft fibrosis and glomerulosclerosis. Chronic allograft nephropathy (CAN) is the histologic description of the fibrosis, vascular and glomerular damage occurring in renal allografts. Clinical programs rely on monitoring change in serum creatinine for identification of patients at risk of CAN, but this change occurs late in the course of the disease, and underestimates the severity of pathologic change. CAN has several causes: ischemia-reperfusion injury, ineffectively or untreated clinical and subclinical rejection, and superimposed calcineurin inhibitor nephrotoxicity, exacerbating pre-existing donor disease. Once established, interstitial fibrosis and arteriolar hyalinosis lead to progressive glomerulosclerosis over the subsequent years. There have been a number of approaches to treatment aimed at reducing the impact of CAN, mostly centered around avoidance of calcineurin inhibitors through their elimination in all, or just selected, patients. These immunosuppression strategies combine corticosteroids with azathioprine or mycophenolate mofetil, and/or sirolimus and everolimus. Late identification of CAN in individual patients has meant that strategies for intervening to prevent chronic renal allograft dysfunction and subsequent graft loss tend to be "too little and far too late."
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The prognostic value of renal resistance during hypothermic machine perfusion of deceased donor kidneys.

            Vascular renal resistance (RR) during hypothermic machine perfusion (HMP) is frequently used in kidney graft quality assessment. However, the association between RR and outcome has never been prospectively validated. Prospectively collected RR values of 302 machine-perfused deceased donor kidneys of all types (standard and extended criteria donor kidneys and kidneys donated after cardiac death), transplanted without prior knowledge of these RR values, were studied. In this cohort, we determined the association between RR and delayed graft function (DGF) and 1-year graft survival. The RR (mmHg/mL/min) at the end of HMP was an independent risk factor for DGF (odds ratio 38.1 [1.56-934]; p = 0.026) [corrected] but the predictive value of RR was low, reflected by a c-statistic of the receiver operator characteristic curve of 0.58. The RR was also found to be an independent risk factor for 1-year graft failure (hazard ratio 12.33 [1.11-136.85]; p = 0.004). Determinants of transplant outcome are multifactorial in nature and this study identifies RR as an additional parameter to take into account when evaluating graft quality and estimating the likelihood of successful outcome. However, RR as a stand-alone quality assessment tool cannot be used to predict outcome with sufficient precision. ©2011 The Authors Journal compilation©2011 The American Society of Transplantation and the American Society of Transplant Surgeons.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Epithelial-mesenchymal transition: An emerging target in tissue fibrosis

              Epithelial-mesenchymal transition (EMT) is involved in a variety of tissue fibroses. Fibroblasts/myofibroblasts derived from epithelial cells contribute to the excessive accumulation of fibrous connective tissue in damaged tissue, which can lead to permanent scarring or organ malfunction. Therefore, EMT-related fibrosis cannot be neglected. This review highlights the findings that demonstrate the EMT to be a direct contributor to the fibroblast/myofibroblast population in the development of tissue fibrosis and helps to elucidate EMT-related anti-fibrotic strategies, which may enable the development of therapeutic interventions to suppress EMT and potentially reverse organ fibrosis.
                Bookmark

                Author and article information

                Journal
                Int J Mol Sci
                Int J Mol Sci
                ijms
                International Journal of Molecular Sciences
                MDPI
                1422-0067
                23 April 2019
                April 2019
                : 20
                : 8
                : 1992
                Affiliations
                [1 ]INSERM U1082 (IRTOMIT), Poitiers F-86000, France; akasil2011@ 123456gmail.com (A.K.); giraudseb@ 123456yahoo.fr (S.G.); pierre.couturier@ 123456outlook.fr (P.C.); akbar_amiri@ 123456hotmail.com (A.A.); jerome.danion@ 123456me.com (J.D.); gianluca.donatini@ 123456chu-poitiers.fr (G.D.); xav.matillon@ 123456gmail.com (X.M.); lionel.badet@ 123456chu-lyon.fr (L.B.)
                [2 ]Faculté de Médecine et Pharmacie, Université de Poitiers, Poitiers F-86000, France
                [3 ]Service d’Urologie et de Chirurgie de la Transplantation, Hôpital Edouard Herriot, Lyon F-69003, France
                [4 ]Service de Biochimie, CHU Poitiers, Poitiers F-86000, France
                [5 ]Plate-forme Infrastrutures en Biologie Sante et Agronomie (IBiSA) MOdélisation Préclinique - Innovations Chirurgicale et Technologique (MOPICT), Domaine Expérimental du Magneraud, Surgères F-17700, France
                [6 ]Service de Chirurgie viscérale, CHU de Poitiers, Poitiers F-86000, France
                [7 ]Université Claude Bernard Lyon 1, Lyon F-69003, France
                [8 ]CarMeN Laboratory, INSERM U1060, Villeurbanne F-69100, France
                [9 ]FHU SUPORT ‘SUrvival oPtimization in ORgan Transplantation’, Poitiers F-86000, France
                Author notes
                [* ]Correspondence: thierry.hauet@ 123456gmail.com ; Tel.: +33-5-49-44-48-29; Fax: +33-5-49-44-38-34
                Author information
                https://orcid.org/0000-0001-8290-721X
                https://orcid.org/0000-0002-6618-3917
                https://orcid.org/0000-0002-0117-071X
                Article
                ijms-20-01992
                10.3390/ijms20081992
                6514898
                31018558
                a08ea3f0-0c03-4ec8-9652-a958219c183f
                © 2019 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 25 March 2019
                : 21 April 2019
                Categories
                Article

                Molecular biology
                dynamic/machine perfusion,oxygen,hemoglobin,ischemia,kidney transplantation
                Molecular biology
                dynamic/machine perfusion, oxygen, hemoglobin, ischemia, kidney transplantation

                Comments

                Comment on this article